MétaCan
Menu
Back to cohort
Record W4323044887 · doi:10.1002/jvc2.100

Efficacy of dupilumab in moderate and severe atopic dermatitis

2023· article· en· W4323044887 on OpenAlexfundno aff
Stephan Weidinger, Eric L. Simpson, Jonathan I. Silverberg, Jochen Schmitt, Yael A. Leshem, Norito Katoh, Zhen Chen, Haixin Zhang, Brad Shumel, Ashish Bansal, Jingdong Chao, Yufang Lü, Ana B. Rossi, Alvina Abramova

Bibliographic record

VenueJEADV Clinical Practice · 2023
Typearticle
Languageen
FieldMedicine
TopicDermatology and Skin Diseases
Canadian institutionsnot available
FundersLEO PharmaGaldermaIncyteMitsubishi Tanabe Pharma CorporationLes Laboratories Pierre FabreRegeneron PharmaceuticalsSanofiValeant Pharmaceuticals InternationalPfizerKyowa Hakko KirinEli Lilly and Company
KeywordsDupilumabAtopic dermatitisMedicinePlaceboConcomitantEczema Area and Severity IndexInternal medicineSeverity of illnessSCORADRandomized controlled trialDermatologyGastroenterologyDermatology Life Quality IndexPathologyDisease

Abstract

fetched live from OpenAlex

Abstract Background Treatment responses may differ between patients with severe versus moderate atopic dermatitis (AD). Objectives To assess dupilumab response by baseline AD severity in adolescent and adult patients with moderate‐to‐severe AD. Methods We assessed dupilumab response by baseline AD severity in 1719 patients aged ≥12 years with moderate‐to‐severe AD from five randomized, double‐blind, placebo‐controlled trials. Patients received subcutaneous placebo or dupilumab as monotherapy (300 mg [adults, adolescents] or 200 mg [adolescents] every 2 weeks; 16 weeks), or with concomitant topical corticosteroids (TCS) (adults; 16/52 weeks). Patients were stratified by baseline Investigator's Global Assessment (IGA) score (3 [moderate]/4 [severe]). Results Dupilumab‐treated patients with moderate AD had numerically higher absolute proportions of patients achieving IGA 0/1 (clear/almost clear) than those with severe AD; risk differences (dupilumab vs. placebo) were 18.9–35.5 for moderate AD and 16.4–34.2 for severe AD. For all other endpoints assessed, no meaningful differences or consistent response patterns between moderate and severe subgroups were observed. Conclusions Dupilumab with or without TCS demonstrated similar efficacy in patients with moderate or severe AD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.012
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.104
Threshold uncertainty score0.996

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.012
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.058
GPT teacher head0.421
Teacher spread0.363 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueJEADV Clinical PracticeSame topicDermatology and Skin DiseasesFrench-language works237,207